Completeness of notifications of severe acute respiratory syndrome at the national level and in a regional health care in the state of Minas Gerais, during the COVID-19 pandemic, 2020

Ribas, Fábio Vieira; Custódio, Ana Cristina Dias; Toledo, Luana Vieira; Henriques, Bruno David; Sediyama, Catarina Maria Nogueira de Oliveira; Freitas, Brunnella Alcântara Chagas de

Acessibilidade / Reportar erro

Brasil

Epidemiologia e Serviços de Saúde

Español English

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

Original article • Epidemiol. Serv. Saúde 31 (2) • 2022 • https://doi.org/10.1590/S1679-49742022000200004 copy

Completeness of notifications of severe acute respiratory syndrome at the national level and in a regional health care in the state of Minas Gerais, during the COVID-19 pandemic, 2020

Authorship SCIMAGO INSTITUTIONS RANKINGS

Abstract

Objective:

To analyze the completeness of notifications of severe acute respiratory syndrome cases on the Influenza Epidemiological Surveillance Information System (SIVEP-Gripe) during the COVID-19 pandemic, on the national database and on the Regional Health Center database of the state of Minas Gerais, Brazil, in 2020.

Methods:

This was a descriptive study of the completeness of sociodemographic variables and those related to etiology, clinical condition, evolution and diagnostic criteria of SIVEP-Gripe. The level of completeness was classified as excellent (> 95%), good (90% to 95%), regular (80% to 90%), poor (50% to 80%) or very poor (< 50%).

Results:

The percentage of variables with excellent completeness was only 18.1% on the national database, and 27.8% on the regional database.

Conclusion:

Both SIVEP-Gripe databases presented low completeness, making it necessary to improve the work process and routine training of professionals aimed at the correct filling.

Keywords:
Severe Acute Respiratory Syndrome; COVID-19; Health Information Systems; Public Health Surveillance

Variables	Completeness
Variables	Regional^c (%)	National^d (%)
1. Race/skin color declared	98.2	78.6
2. Schooling level	33.9	37.2
3. ZIP Code^e of place of residence	95.9	100.0
4. Geographic area of residential address	96.6	88.6
5. Case arising from flu-like syndrome outbreak	93.5	71.0
6. Case of SARS with hospital-acquired infection	92.5	69.9
7. Case with direct contact with birds, pigs, others	90.7	66.1

Variables	Completeness
	Regional^c (%)	National^d (%)
	(n = 2,590)	(n = 1,192,518)
Signs and symptoms
1. Fever	96.6	85.3
2. Cough	97.4	87.6
3. Sore throat	94.8	72.6
4. Dyspnea	97.7	87.7
5. Respiratory distress	96.9	82.2
6. Saturation < 95%	96.1	82.2
7. Diarrhea	94.7	71.7
8. Vomiting	94.4	70.6
9. Abdominal pain	91.5	42.0
10. Fatigue	91.3	43.2
11. Loss of smell	91.2	41.6
12. Loss of taste	91.1	41.9
13. Other signs and symptoms	90.1	71.1
Risk factors
14. Presents a risk factor	100.0	100.0
15. Puerperal woman	61.6	39.1
16. Chronic cardiovascular disease	62.7	51.1
17. Chronic hematologic disease	61.2	39.3
18. Down syndrome	61.3	39.3
19. Chronic liver disease	61.2	39.2
20. Asthma	61.4	40.2
21. Diabetes mellitus	62.7	47.5
22. Neurological disorders	61.5	40.5
23. Chronic lung disease	61.6	40.5
24. Immunodeficiency ou immunodepression	61.2	39.8
25. Chronic kidney disease	61.5	40.2
26. Obesity	61.3	39.8
26.1 Body mass index - BMI (obese)	19.1	47.3
27. Other risk factors	60.7	46.8
27.1 Description of other morbidities	98.0	98.8
Vaccination history
28. Got vaccinated against influenza in the last campaign	72.3	40.1
28.1 Date of his/her last dose of influenza vaccine	66.9	66.7
29. His/her mother got vaccinated against influenza (for those under 6 months old)	47.8	29.8
30. Mother breastfeeds her child (for those under 6 months old)	39.1	30.1
Other clinical information
31. Used antiviral medications to treat the disease	83.6	72.3
31.1 Antiviral medication used (oseltamivir, zanamivir, other)	94.7	93.8
31.2 Description of another antiviral medication used	88.9	70.8
31.3 Date of antiviral treatment initiation	93.1	91.9
32. Need for hospitalization	98.8	97.0
32.1 Date of hospitalization	96.2	98.3
32.2 Federative Unit where the hospitalization occurred	95.4	100.0
32.3 Municipality where the hospitalization occurred	95.4	100.0
32.4 Sentinel unit where the hospitalization occurred	95.4	100.0
33. Need to be hospitalized in the ICU^e	92.2	83.5
33.1 Date of admission in the ICU	99.0	97.7
33.2 Date of discharge from the ICU	19.9	51.8
34. He/she used ventilatory support	86.9	82.1
35. Evolution of the case	87.7	85.5
35.1 Date of discharge of death	46.6	89.9
36. Date of case closure	88.0	88.2

Variables	Completeness
	Regional^c (%)	National^d (%)
	(n = 2,590)	(n = 1,192,518)
Imaging tests
1. Chest X-ray	67.6	55.7
1.1 Specifications of other chest X-ray results	63.0	86.6
1.2 Date of chest X-ray	87.0	90.6
2. CT scan aspect	35.7	32.4
2.1 Date of CT scan procedure	88.1	90.3
Sample collection
3. Sample collection was performed for diagnostic test	98.3	96.3
3.1 Date of sample collection for diagnostic test	100.0	100.0
3.2 Type of clinical sample collected for diagnostic test	98.8	97.9
3.3 Specification of another sample that was collected	98.5	96.0
Antigen rapid test
3.4 Type of antigen rapid test that was performed	34.8	41.0
3.4.1 Date of antigen rapid test result	9.2	6.9
3.5 Antigen rapid test result	94.3	84.8
3.5.1 Positive antigen rapid test result for influenza	2.2	2.9
RT-PCR^e
3.6 RT-PCR test result/another method applying molecular biology	98.3	99.2
3.6.1 Date of RT-PCR test result/another method applying molecular biology	92.4	89.8
3.7 Positive RT-PCR test result for influenza	93.8	21.8
3.7.1 Positive RT-PCR test result for influenza A or B	100.0	99.8
Serological test
3.8 Type of serological sample that was collected	4.8	8.5
3.8.1 Description of the type of clinical sample different from those afore mentioned	52.4	101.9ⁱ
3.9 Date of collection of the material for serological diagnosis	5.4	8.0
3.10 Type of serological test that was performed	3.5	8.9
3.10.1 Description of the type of serological test that was performed	100.0	0.2
3.11 Serology result for SARS-CoV-2 IgG^f	4.0	10.8
3.12 Serology result for SARS-CoV-2 IgM^g	4.1	11.1
3.13 Serology result for SARS-CoV-2 IgA^h	0.8	6.8
Outcome
4. Final classification of the case	94.0	93.9
4.2 Indicate confirmation criterion	92.8	91.4

Secretaria de Vigilância em Saúde e Ambiente - Ministério da Saúde do Brasil SRTVN Quadra 701, Via W5 Norte, Lote D, Edifício P0700, CEP: 70719-040, +55 61 3315-3464, Fax: +55 61 3315-3464 - Brasília - DF - Brazil
E-mail: ress.svs@gmail.com

Acompanhe os números deste periódico no seu leitor de RSS

[1] Correspondence Fábio Vieira Ribas fabioribas83@yahoo.com.br